Mazdutide Phase 4 Trial QUARTET-DKD Registered, Not Yet Recruiting

On August 20, 2026, a new Phase 4 clinical trial listing involving mazdutide appeared on ClinicalTrials.gov. The trial, titled "QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy," is registered under identifier NCT07775846. Its current status is listed as not yet recruiting. The study is designated as a Phase 4 trial, indicating it is intended to follow prior approval-stage research for the therapy combination under investigation. No participant enrollment has begun as of the listing date. The trial record does not yet include reported outcomes, results, or efficacy data. As a not yet recruiting study, further details such as enrollment timelines and site locations may be updated as the trial progresses. Mazdutide remains classified as an unapproved compound under research status. This listing reflects only the registration of the trial and its current administrative status, not any findings about mazdutide's safety or effectiveness in this context. Readers interested in the broader development background of mazdutide can consult the compound overview for additional context on its research history and current regulatory standing.